Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: RFA-NS-28-012
Official listed status: posted
Closing information: 2028-10-10 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 2,500,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: Special district governments; Small businesses; Independent school districts; City or township governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Public housing authorities/Indian housing authorities; Native American tribal organizations (other than Federally recognized tribal governments); State governments; Native American tribal governments (Federally recognized); Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Private institutions of higher education
Federal synopsis
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.